查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年腦癱治療的全球市場
市場調查報告書
商品編碼
1272770

2023-2030 年腦癱治療的全球市場

Global Cerebral Palsy Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球腦癱治療市場預計將實現利潤豐厚的增長，到 2022 年將達到 32.074 億美元，到 2030 年將達到 42.805 億美元。 全球腦癱治療市場預計在預測期內（2023-2030 年）的複合年增長率為 3.7%。 主要參與者正在採取合作夥伴關係、合併、收購和地域擴張等戰略，以在腦癱治療市場中脫穎而出，成為強大的競爭對手。 新產品的發布和對研發的更多關注是領先公司增加市場影響力的其他一些方式。

例如，2021 年 8 月 31 日，Merz Group 的一個部門宣布使用 XEOMIN 緩解體重低於 12 公斤的兒童和青少年因神經或神經發育障礙引起的慢性流涎症狀。在歐盟層面，由神經毒素領域的先驅 Merz Therapeutics 提供。

腦癱 (CP) 是一組以身體僵硬和運動障礙為特徵的非進行性慢性疾病。 當大腦在子宮內發育不正常或出生後發生損傷時，就會出現這種情況。 它影響四肢的運動功能，導致平衡障礙、肌肉收縮、不協調和其他神經系統症狀。

最常見的腦癱類型是痙攣型、共濟失調型和混合型。 治療包括藥物、療法、手術和其他改善日常功能的治療。 腦癱無法治愈。

此外，腦癱患病率的增加、臨床試驗的快速進行以及政府資金和企業投資的增加是預計在預測期內推動市場增長的關鍵因素。

市場動態

早產患病率上升推動全球腦癱治療市場增長

早產、低出生體重、多胞胎和妊娠期感染導致腦癱病例增加。 據估計，每年有 1500 萬嬰兒早產，其中超過十分之一屬於此類。 每年有超過 100 萬兒童死於早產並發症。 許多倖存者可能面臨終生殘疾，例如學習障礙以及視力和聽力障礙。

此外，甲狀腺疾病、癲癇發作和智力障礙等孕產婦健康問題也可能引發兒童腦癱。 此外，腦癱治療市場的快速增長歸因於腦癱發病率的增加、家長對腦癱並發症的認識提高以及市場上各種治療方案的可用性。人們認為。

例如，根據美國疾病控制和預防中心的數據，美國每 1,000 名兒童中就有 1.5 到 4 名患有腦癱。 這種情況是由控制運動、姿勢和平衡的大腦區域發育異常或受損引起的。 腦癱最常發生在出生前，但也可能在出生時或出生後不久出現困難。 因此，由於上述因素，預計腦癱治療市場將在預測期內獲得牽引力。

腦癱治療市場的增長受到藥物急性副作用的阻礙

藥物是腦癱治療的重要組成部分，有助於控制症狀和改善生活質量，但它們也可能有副作用。 例如，肌肉鬆弛劑會導致嗜睡和疲勞，影響人的日常生活活動，並影響學校或工作。

此外，解痙藥在用於治療腦癱時會引起胃腸道問題，例□□如便秘、腹瀉和腹脹。 因此，由於上述因素，預計預測期內腦癱治療市場將受到阻礙。

COVID-19 影響分析

COVID-19 對腦癱治療市場產生了重大影響。 醫療機構優先考慮 COVID-19 患者，導致非緊急護理的延誤和取消。 大流行減少了獲得醫療保健服務的機會，使腦癱患者更難獲得所需的護理。

此外，大流行還擾亂了藥品和醫療設備的供應鏈，使醫護人員更難治療腦癱患者。 同樣，它影響了用於治療腦癱的藥物的開發、生產和分配，包括臨床試驗的延誤。

另一方面，由於難以直接到醫療機構就診，遠程醫療服務正在普及，但目前的情況是，它們不一定能替代腦癱患者面對面的醫療服務。

俄烏衝突分析

俄羅斯入侵烏克蘭造成了一場人道主義危機，對智障人士及其家人造成了不成比例的影響。 孤兒院的殘疾兒童因缺乏活動和痙攣性腦癱治療而變得扭曲和抽筋，因此慈善機構定期提供止痛治療。 同樣，全球兒童基金會在烏克蘭的合作夥伴正在幫助殘疾兒童及其家人撤離到更安全的地區並獲得所需的物資。 因此，衝突對全球腦癱治療市場產生了一定影響。

人工智能影響分析

AI 系統改進了腦癱兒童的預後並支持管理選擇。 例如，斯坦福大學和明尼蘇達州吉列兒童專科醫院的研究人員使用人工智能和單個攝像頭拍攝的視頻來分析被診斷為腦癱患者的運動障礙。 該系統價格低廉、易於使用且開源，使醫生能夠更好地識別、衡量進展並治療神經和肌肉骨骼疾病。

內容

第一章調查方法及範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按藥物類型分類的片段
  • 疾病片段
  • 按銷售渠道分類的摘要
  • 區域摘要

第四章市場動態

  • 影響因素
    • 主持人
      • 早產患者的增加推動了預測期內腦癱治療市場的增長
    • 約束因素
      • 藥物的急性副作用將在預測期內阻礙腦癱治療市場的增長
    • 機會
      • 合作研究的增加
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章俄烏衝突分析

第8章人工智能的影響分析

第9章按藥物類型分類

  • 抗驚厥藥
  • 抗膽鹼藥
  • 抗抑鬱藥
  • 其他

第 10 章按疾病類型分類

  • 痙攣性腦癱
  • 混合性腦癱
  • 運動障礙性腦癱
  • 共濟失調性腦癱

第 11 章分銷渠道

  • 醫院藥房
  • 零售店和配藥店
  • 在線藥店

第12章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第13章競爭格局

  • 競爭場景
  • 產品基準
  • 公司股票分析
  • 主要發展和戰略

第14章公司簡介

  • Merz Pharmaceuticals, LLC。
    • 公司概況
    • 產品組合和說明
    • 財務摘要
    • 主要發展狀況
  • Pfizer Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Novartis
  • AbbVie Inc.
  • Par Pharmaceutical
  • Hikma Pharmaceuticals Plc.

第15章 附錄

簡介目錄
Product Code: PH4902

Market Overview

The global cerebral palsy treatment market reached US$ 3,207.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,280.5 million by 2030. The global cerebral palsy treatment market is expected to exhibit a CAGR of 3.7% during the forecast period (2023-2030). The key players are adopting strategies such as partnerships, mergers, acquisitions, and regional expansion to stand out as strong competitors in the cerebral palsy treatment market. Novel product launches and enhanced focus on research and development are some of the other ways where the leading players can improve their market presence.

For instance, on August 31, 2021, the use of XEOMIN for the relief of symptoms of chronic sialorrhea caused by neurological or neurodevelopmental disorders in children and adolescents weighing less than 12 kg has been approved on an EU level for Merz Therapeutics, a division of the Merz Group and a pioneer in the field of neurotoxins.

Cerebral Palsy (CP) is a collection of non-progressive, chronic illnesses marked by stiffness and mobility disability. It arises when the brain does not develop normally in the womb or due to a post-natal injury. It can affect motor function in all four limbs, resulting in balance issues, muscular contracture, coordination issues, and other neurological symptoms.

The most common cerebral palsy is spastic, ataxic dyskinetic, and mixed. Treatment options include medications, therapies, surgical procedures, and other treatments to improve daily functioning. There is no cure for cerebral palsy.

Furthermore, the increasing prevalence of cerebral palsy disorder, rapid clinical trials, and increasing government funding and company investments are key factors expected to drive the market growth over the forecast period.

Market Dynamics

The increasing prevalence of premature births is boosting the global cerebral palsy treatment market growth

Premature birth, low birth weight, multiple childbirths, and infectious diseases during pregnancy can lead to a rise in cerebral palsy cases. An estimated 15 million babies are born prematurely yearly, with more than one out of every ten falling under this category. Every year, over one million children die due to premature birth complications. Many survivors may face obstacles for the rest of their life, such as learning disabilities and visual and hearing problems.

Moreover, health problems in the mother, such as thyroid illness, seizures, intellectual impairment, and so on, might induce cerebral palsy in the kid. In addition, the rapid growth of the cerebral palsy treatment market can be attributed to an increase in the incidence of cerebral palsy and an increase in parental awareness of cerebral palsy complications, and the availability of various treatment options in the market.

For instance, according to the Centres for Disease Control and Prevention, 1.5 to 4 children out of every 1000 in the United States have cerebral palsy. The condition is caused by aberrant development or injury to brain regions that govern movement, posture, and balance. Cerebral palsy is most frequent before birth, but difficulties can arise during or immediately after birth. Thus, from the above factors, the cerebral palsy treatment market is expected to drive over the forecast period.

Acute side effects due to medications are hampering the growth of the global cerebral palsy treatment market

Medications are an important part of cerebral palsy treatment, helping to manage symptoms and improve quality of life, but can also have side effects. For instance, muscle relaxants can cause drowsiness and fatigue, which can affect a patient's ability to perform daily activities and interfere with their school or work.

Similarly, antispasmodics can cause gastrointestinal disturbances when used to treat cerebral palsy, such as constipation, diarrhea, and bloating. Hence, owing to the above factors, the cerebral palsy treatment market is expected to be hampered over the forecast period.

COVID-19 Impact Analysis

COVID-19 has had a significant impact on the cerebral palsy treatment market. Healthcare facilities have prioritized COVID-19 patients, leading to delays or cancellations of non-emergency treatments. The pandemic has caused reduced access to healthcare services, making it more difficult for patients with cerebral palsy to access the care they need.

Moreover, the pandemic has disrupted supply chains for medications and medical equipment, making it more difficult for healthcare providers to treat patients with cerebral palsy. Likewise, it had a sign on the development, production, and distribution of drugs used to treat cerebral palsy, including delayed clinical trials.

In contrast, telemedicine services have become increasingly popular due to the difficulty of visiting healthcare facilities in person, but it is not always a substitute for in-person care for patients with cerebral palsy.

Russia-Ukraine Conflict Analysis

Russia's invasion of Ukraine has caused a humanitarian crisis, disproportionately impacting people with intellectual disabilities and their families. Children in orphanages with disabilities had become twisted and constricted due to lack of activity and treatment for spastic cerebral palsy, so charitable organizations provided regular treatments to reduce pain. Similarly, global fund for Children partners in Ukraine is helping children with disabilities and their families evacuate to safer areas and get essential supplies. Therefore, the conflict has had a moderate impact on the global cerebral palsy treatment market.

Artificial Intelligence Impact Analysis

AI systems help to refine prognosis and assist in management selection for children with cerebral palsy. For instance, researchers at Stanford and Gillette Children's Specialty Hospital in Minnesota have used artificial intelligence and video shot with a single camera to analyze movement impairment in people diagnosed with cerebral palsy. This system is inexpensive, easy to use, and open-source, allowing doctors to better identify, measure progress, and treat neurological and musculoskeletal disorders.

Segment Analysis

The global cerebral palsy treatment market is segmented based on drug type, disease type, distribution channel, and region.

The spastic cerebral palsy segment is expected to hold a dominant position in the market over the forecast period

The spastic cerebral palsy segment accounted for the highest market stake accounting for approximately 70.4% of the cerebral palsy treatment market in 2022. Spastic cerebral palsy is a developmental disorder caused by brain damage before birth, during delivery, or in the first few years of life. Children are the most affected and develop co-occurring symptoms, driving revenue growth in this segment.

Spastic CP, such as quadriplegia, hemiplegia, and diplegia, affects the body the most. Treatment options such as physical therapy, medication, baclofen pump, spine or cord surgery, muscle release, and tendon lengthening surgery are used to prevent symptoms, creating demand for this segment.

Moreover, companies such as Merz Pharmaceuticals, Teva Pharmaceuticals, Supernus Pharmaceuticals, and Rohto Pharmaceutical are conducting clinical trials to explore new treatment options, driving revenue growth.

Geographical Analysis

The increasing prevalence of cerebral palsy disorder, and increasing funding by government organizations to dominate the North America region

North America is expected to dominate the worldwide cerebral palsy treatment market, accounting for around 2/5th of this market, with the U.S. being the major contributor. For instance, the U.S. government offers a variety of financial benefits to people with cerebral palsy, such as benefit programs, scholarships, grants, and subsidized loans. The most common resources are Supplemental Security Income (SSI), the Individuals With Disabilities Education Act (IDEA), and Medicaid.

Competitive Landscape

The major global players in the market include Merz Pharmaceuticals, LLC., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical, and Hikma Pharmaceuticals Plc among others.

Why Purchase the Report?

  • To visualize the global cerebral palsy treatment market segmentation based on the drug type, disease type, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cerebral palsy treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global cerebral palsy treatment market report would provide approximately 61 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Disease Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of premature births is boosting the global cerebral palsy treatment market growth during the forecast period.
    • 4.1.2. Restraints
      • 4.1.2.1. Acute side effects due to medications are hampering the growth of the global cerebral palsy treatment market in the forecast period.
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing collaborative research efforts
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Artificial Intelligence Impact Analysis

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Anticonvulsants*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Anticholinergics
  • 9.4. Antidepressants
  • 9.5. Other

10. By Disease Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.1.2. Market Attractiveness Index, By Disease Type
  • 10.2. Spastic Cerebral Palsy*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Mixed Cerebral Palsy
  • 10.4. Dyskinetic Cerebral Palsy
  • 10.5. Ataxic Cerebral Palsy

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail stores and Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. The U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. The U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Merz Pharmaceuticals, LLC. *
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Pfizer Inc.
  • 14.3. Viatris Inc.
  • 14.4. Teva Pharmaceutical Industries Ltd.
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. GlaxoSmithKline plc.
  • 14.7. Novartis
  • 14.8. AbbVie Inc.
  • 14.9. Par Pharmaceutical
  • 14.10. Hikma Pharmaceuticals Plc.

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us